Equity Field Notes from temporal sources

[DanWebzster]

TENX is an ultra-low float biotech with one treatment its pipeline.

Levosimendan will go into a Ph2 study to treat PH-HFpEF during H-2/18.

PH-HFpEF is high blood pressure in the arteries supplying the lung. Presently, there is no approved drug for this condition. Supplemental O2 is used to alleviate symptoms.

Levo is a compound with a a 16-yr history of use in Europe. Its inotropic and lusitropic properties are an indication that it may work in PH-HFpEF.

12/31/17 Cash = $9.5mn. Burn has been ~$1.6mn / Q ; but, expenses will increase significantly when the Ph2 begins during H2/18.